Ebru Arhan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ebru Arhan has a total of 291 co-authors. Here are the top co-authors by number of shared publications:
Ayse Serdaroglu
Department of Child Neurology, Gazi University Faculty of Medicine, Ankara, Turkey
9 shared publications- Kürşad Aydın
Department of Pediatric Neurology, Faculty of Medicine, Medipol University, İstanbul, Turkey
7 shared publications - Esra Serdaroğlu
Department of Pediatric Neurology, Gazi University Faculty of Medicine, Ankara, Turkey
6 shared publications - Tuğba Hirfanoğlu
Section of Child Neurology, Department Pediatrics, Faculty of Medicine, Gazi University, Ankara, Turkey
6 shared publications - Ayşe Serdaroğlu
Section of Child Neurology, Department Pediatrics, Faculty of Medicine, Gazi University, Ankara, Turkey
5 shared publications - Ayşe Serdaroğlu
Department of Pediatric Neurology, Gazi University Faculty of Medicine, Ankara, Turkey
4 shared publications
Latest Publications
- 21 July 2026
- Published by Elsevier in Epilepsy Research
- Vol. 227, 107878
Beyond behavioral activation: A prospective item-level analysis of the neuro-psychiatric trajectory of pediatric epilepsy patients treated with levetiracetam
- 21 July 2026
- Published by Elsevier in Epilepsy Research
- Vol. 227, 107878
Beyond behavioral activation: A prospective item-level analysis of the neuro-psychiatric trajectory of pediatric epilepsy patients treated with levetiracetam
- Open Access
- 15 July 2026
- Published by Academician Publishing
Çocukluk Çağında Otizm Spektrum Bozukluğu
- 15 July 2026
- Published by Academician Publishing
Open AccessÇocukluk Çağında Otizm Spektrum Bozukluğu
- 15 July 2026
- Published by Academician Publishing
- p. 477-494
Otizm ve Uyku Bozuklukları: Tanı ve Tedavi
- 10 July 2026
- Published by Elsevier in Epilepsy Research
- Vol. 226, 107872
Ketogenic diet enhances cardiac autonomic stability in pediatric drug-resistant epilepsy: A longitudinal heart rate variability study
- 10 July 2026
- Published by Elsevier in Epilepsy Research
- Vol. 226, 107872
Ketogenic diet enhances cardiac autonomic stability in pediatric drug-resistant epilepsy: A longitudinal heart rate variability study
- 23 March 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 179, 111015
The efficacy and tolerability of lacosamide adjunctive therapy in children with drug-refractory epilepsy: A nationwide Turkish cohort study
- 23 March 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 179, 111015
The efficacy and tolerability of lacosamide adjunctive therapy in children with drug-refractory epilepsy: A nationwide Turkish cohort study
- 1 March 2026
- Published by ASEAN Neurological Association in Neurology Asia
- Vol. 31 (1) , 239-246
Psychiatric comorbidity may affect the quality of life in pediatric migraine patients, independently of pain frequency and PedMIDAS score
Background: Migraine is a prevalent neurological disorder in children, often accompanied by psychiatric comorbidities (PC) such as depression, anxiety, and attention deficit hyperactivity disorder (ADHD). These conditions significantly affect children’s lives, particularly their self-esteem, social relationships, and overall quality of life (QOL). However, research on the combined impact of migraine and PC on pediatric QOL remains limited. Methods: This study included 175 children aged 8–17 years from the Pediatric Neurology Outpatient Clinic of a tertiary hospital. Among them, 75 were diagnosed with migraine and 100 served as controls. Data on sociodemographic factors, migraine-related disability (PedMIDAS), PC, and QOL (KINDLR questionnaire) were collected. Results: Major depression, ADHD, and oppositional defiant disorder were significantly more prevalent in the migraine group compared to controls. Children with episodic migraine and PC had markedly lower self-esteem, poorer social relationships, and overall QOL than those without comorbidities. Conversely, no significant QOL differences were observed between children with and without PC in the chronic migraine group. Furthermore, no correlation was found between PedMIDAS scores and QOL in migraine patients. Psychiatric comorbidities were associated with lower QOL in children with migraine, particularly in those with episodic migraine, with notable reductions in self-esteem and social relationships. PedMIDAS, while useful for assessing migraine-related disability, may not fully reflect the QOL differences associated with PC. Conclusion: Comprehensive evaluation of both QOL and PC is essential for effective management and follow-up of pediatric migraine patients.
- 1 March 2026
- Published by ASEAN Neurological Association in Neurology Asia
- Vol. 31 (1) , 239-246
Psychiatric comorbidity may affect the quality of life in pediatric migraine patients, independently of pain frequency and PedMIDAS score
Background: Migraine is a prevalent neurological disorder in children, often accompanied by psychiatric comorbidities (PC) such as depression, anxiety, and attention deficit hyperactivity disorder (ADHD). These conditions significantly affect children’s lives, particularly their self-esteem, social relationships, and overall quality of life (QOL). However, research on the combined impact of migraine and PC on pediatric QOL remains limited. Methods: This study included 175 children aged 8–17 years from the Pediatric Neurology Outpatient Clinic of a tertiary hospital. Among them, 75 were diagnosed with migraine and 100 served as controls. Data on sociodemographic factors, migraine-related disability (PedMIDAS), PC, and QOL (KINDLR questionnaire) were collected. Results: Major depression, ADHD, and oppositional defiant disorder were significantly more prevalent in the migraine group compared to controls. Children with episodic migraine and PC had markedly lower self-esteem, poorer social relationships, and overall QOL than those without comorbidities. Conversely, no significant QOL differences were observed between children with and without PC in the chronic migraine group. Furthermore, no correlation was found between PedMIDAS scores and QOL in migraine patients. Psychiatric comorbidities were associated with lower QOL in children with migraine, particularly in those with episodic migraine, with notable reductions in self-esteem and social relationships. PedMIDAS, while useful for assessing migraine-related disability, may not fully reflect the QOL differences associated with PC. Conclusion: Comprehensive evaluation of both QOL and PC is essential for effective management and follow-up of pediatric migraine patients.
- Open Access
- 8 October 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (12) , 7079-7080
Correction to: Lower risk of seizure recurrence with levetiracetam and oxcarbazepine after withdrawal in pediatric epilepsy: a pilot study
- 8 October 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (12) , 7079-7080
Open AccessCorrection to: Lower risk of seizure recurrence with levetiracetam and oxcarbazepine after withdrawal in pediatric epilepsy: a pilot study
- 20 September 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (12) , 6755-6762
Lower risk of seizure recurrence with levetiracetam and oxcarbazepine after withdrawal in pediatric epilepsy: a pilot study
Introduction There is no consensus on the optimal timing for discontinuing antiseizure medications (ASMs) and the associated risk factors for seizure recurrence in children with epilepsy. This study aimed to assess the ideal timing for discontinuation, the frequency and predictors of seizure recurrence, the risk factors associated with the cessation of ASMs and the potential impact of specific ASMs on seizure recurrence in children with epilepsy. Methods The study included 211 children aged between one month and fifteen years who had been treated with ASMs and were followed for a minimum of two years after medication withdrawal. Results The overall seizure recurrence rate was 30% with 75% of these recurrences occurring during the tapering period and within the first year after ASM withdrawal. The risk of seizure recurrence was significantly lower in patients using levetiracetam and oxcarbazepine compared to those taking valproate and carbamazepine. Specifically, the seizure recurrence rates were significantly lower in levetiracetam group than valproate (p = 0.006) and carbamazepine (p = 0.025) groups. Similarly, children taking oxcarbazepine experienced fewer seizure recurrences compared to those receiving carbamazepine (p = 0.011). In multivariate Cox regression analysis, a treatment duration less than three years was identified as the main risk factor for seizure recurrence (OR: 2.974, CI: 1.684–5.252, p value: 0.001). Conclusion The risk of seizure recurrence was lower in patients treated with newer generation ASMs, levetiracetam and oxcarbazepine compared to those using valproate and carbamazepine. We suggest that ASMs should be continued for at least three years before considering treatment discontinuation.
- 20 September 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (12) , 6755-6762
Lower risk of seizure recurrence with levetiracetam and oxcarbazepine after withdrawal in pediatric epilepsy: a pilot study
Introduction There is no consensus on the optimal timing for discontinuing antiseizure medications (ASMs) and the associated risk factors for seizure recurrence in children with epilepsy. This study aimed to assess the ideal timing for discontinuation, the frequency and predictors of seizure recurrence, the risk factors associated with the cessation of ASMs and the potential impact of specific ASMs on seizure recurrence in children with epilepsy. Methods The study included 211 children aged between one month and fifteen years who had been treated with ASMs and were followed for a minimum of two years after medication withdrawal. Results The overall seizure recurrence rate was 30% with 75% of these recurrences occurring during the tapering period and within the first year after ASM withdrawal. The risk of seizure recurrence was significantly lower in patients using levetiracetam and oxcarbazepine compared to those taking valproate and carbamazepine. Specifically, the seizure recurrence rates were significantly lower in levetiracetam group than valproate (p = 0.006) and carbamazepine (p = 0.025) groups. Similarly, children taking oxcarbazepine experienced fewer seizure recurrences compared to those receiving carbamazepine (p = 0.011). In multivariate Cox regression analysis, a treatment duration less than three years was identified as the main risk factor for seizure recurrence (OR: 2.974, CI: 1.684–5.252, p value: 0.001). Conclusion The risk of seizure recurrence was lower in patients treated with newer generation ASMs, levetiracetam and oxcarbazepine compared to those using valproate and carbamazepine. We suggest that ASMs should be continued for at least three years before considering treatment discontinuation.
- 26 June 2025
- Published by Wiley in Epileptic Disorders
- Vol. 27 (5) , 901-910
Electrophysiological and clinical markers of SUDEP risk in pediatric epilepsy
Objective: Sudden unexpected death in epilepsy (SUDEP) is a major cause of epilepsy‐related mortality, especially in patients with drug‐resistant epilepsy. However, pediatric data remain limited, and specific risk assessment tools for children are lacking. This study evaluates the association between peri‐ictal prone positioning, postictal generalized EEG suppression (PGES), and SUDEP‐7 Inventory scores in pediatric patients with epilepsy. Methods: A retrospective review was conducted on 273 generalized convulsive seizures (GCS) from 117 pediatric patients who underwent video‐EEG monitoring from 2002 to 2022. We assessed body position during seizures, PGES presence and duration, and SUDEP‐7 Inventory scores. Statistical comparisons were made across PGES‐positive and ‐negative, and prone vs. non‐prone subgroups. Results: Prone positioning occurred in 5.86% of seizures, with 91.6% of prone‐onset seizures remaining in the prone position throughout. PGES was present in 50.4% of patients (mean duration: 120.5 s). SUDEP‐7 scores were significantly higher in PGES‐positive patients (mean: 7.04) compared to PGES‐negative (mean: 6.36; p = 0.031). Daytime GCS occurred significantly earlier after sleep onset than night time GCS (53.3 vs. 131.4 minutes; p = 0.001). Significance: PGES appears to be a reliable marker associated with higher SUDEP‐7 scores and may indicate increased SUDEP risk in children. While SUDEP‐7 has limitations in pediatric use, it remains the most accessible clinical tool. Integrating EEG and body position metrics could enhance individualized monitoring for pediatric patients at risk.
- 26 June 2025
- Published by Wiley in Epileptic Disorders
- Vol. 27 (5) , 901-910
Electrophysiological and clinical markers of SUDEP risk in pediatric epilepsy
Objective: Sudden unexpected death in epilepsy (SUDEP) is a major cause of epilepsy‐related mortality, especially in patients with drug‐resistant epilepsy. However, pediatric data remain limited, and specific risk assessment tools for children are lacking. This study evaluates the association between peri‐ictal prone positioning, postictal generalized EEG suppression (PGES), and SUDEP‐7 Inventory scores in pediatric patients with epilepsy. Methods: A retrospective review was conducted on 273 generalized convulsive seizures (GCS) from 117 pediatric patients who underwent video‐EEG monitoring from 2002 to 2022. We assessed body position during seizures, PGES presence and duration, and SUDEP‐7 Inventory scores. Statistical comparisons were made across PGES‐positive and ‐negative, and prone vs. non‐prone subgroups. Results: Prone positioning occurred in 5.86% of seizures, with 91.6% of prone‐onset seizures remaining in the prone position throughout. PGES was present in 50.4% of patients (mean duration: 120.5 s). SUDEP‐7 scores were significantly higher in PGES‐positive patients (mean: 7.04) compared to PGES‐negative (mean: 6.36; p = 0.031). Daytime GCS occurred significantly earlier after sleep onset than night time GCS (53.3 vs. 131.4 minutes; p = 0.001). Significance: PGES appears to be a reliable marker associated with higher SUDEP‐7 scores and may indicate increased SUDEP risk in children. While SUDEP‐7 has limitations in pediatric use, it remains the most accessible clinical tool. Integrating EEG and body position metrics could enhance individualized monitoring for pediatric patients at risk.
- 9 March 2025
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 127, 71-76
Evaluation of lateralization and localization value of hand postures in Pediatric Epilepsy
- 9 March 2025
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 127, 71-76
Evaluation of lateralization and localization value of hand postures in Pediatric Epilepsy